Topical delivery of nonsteroidal anti-inflammatory drugs for osteoarthritis

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 26, Issue 1, 2012, Pages 18-23

  Herndon, Christopher M ^a  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

diclofenac; NSAID; osteoarthritis; topical

Indexed keywords

ALCOHOL; DICLOFENAC; DICLOFENAC EPOLAMINE; DIMETHYL SULFOXIDE; EMOLLIENT AGENT; KETOPROFEN; MELOXICAM; PHOSPHATIDYLCHOLINE; PIROXICAM; PLACEBO; PROPYLENE GLYCOL;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ARTHRALGIA; ARTICLE; BACKACHE; CONJUNCTIVITIS; CONTACT DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRY SKIN; DYSPEPSIA; GEL; HUMAN; KNEE OSTEOARTHRITIS; LIPID BILAYER; LIVER FUNCTION TEST; MONOTHERAPY; NAUSEA; OSTEOARTHRITIS; PAIN; PRURITUS; RASH; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN IRRITATION; SKIN PENETRATION; STRATUM CORNEUM; SYNOVIAL FLUID; TREATMENT RESPONSE; VISION;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; GELS; HUMANS; LECITHINS; MODELS, BIOLOGICAL; OSTEOARTHRITIS; PERMEABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859010396     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2011.653600     Document Type: Article

References (36)

1. Altman RD. New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. Curr Med Res Opin. 2010;26:2871-2876.
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates ofthe prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
3. Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2006;33:567-573. (Pubitemid 43334582)
4. Recommendations for themedical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905-1915.
5. Jordan KM, Arden NK, DohertyM, et al. EULAR Recommendations 2003: anevidence based approach to themanagement of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155. (Pubitemid 37500619)
6. Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs. 2011;71:1259-1279.
7. Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010;11:535-549.
8. Voltaren Gel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2009.
9. Pennsaid (diclofenac sodium topical solution) 1.5% w/w [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc; 2010.
10. Solaraze Gel (diclofenac sodium) 3%[package insert].Melville, NY: PharmaDerm; 2010.
11. Flector Patch (diclofenac epolamine 1.3%) [package insert]. Bristol, TN: King Pharmaceuticals Inc; 2011.
12. Conte A, Ronca G, Petrini M, Mautone G. Effect of lecithin on epicutaneous absorption of diclofenac epolamine. Drugs Exp Clin Res. 2002;28:249-255. (Pubitemid 36596890)
13. Barry BW. Penetration enhancers. In: Shroot B, Schaefer H, eds. Skin Pharmacokinetics. Pharmacology and Skin; Vol. 1. Basel: Karger; 1987.
14. Wiechers JW. The barrier function ofthe skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci. 1989;11:185-198. (Pubitemid 20057218)
15. Tanojo H, Wester RC, Shainhouse JZ, Maibach HI. Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin. Eur J Drug Metab Pharmacokinet. 1999;24:345-351. (Pubitemid 30342703)
16. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603-618. (Pubitemid 38326936)
17. Morimoto H,Wada Y, Seki T, Sugibayashi K. In vitro skin permeation of morphine hydrochloride during the finite application of penetration-enhancing system containing water, ethanol and l-menthol. Biol Pharm Bull. 2002;25:134-136.
18. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. Percutaneous absorption enhancement af an ionic molecule by ethanol-water systems in human skin. Pharm Res. 1990;7:762-766. (Pubitemid 20278377)
19. Berner B,Mazzenga GC, Otte JH, Steffens RJ, Juang RH, Ebert CD. Ethanol: water mutually enhanced transdermal therapeutic system II: skin permeation of ethanol and nitroglycerin. J Pharm Sci. 1989;78:402-407. (Pubitemid 20070550)
20. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther. 1994;268:144-151. (Pubitemid 24039081)
21. Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frölich JC. Diclofenac concentrations insynovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol. 1991;31:537-541.
22. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability oftopical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010;50:50-61.
23. Gurtovenko AA, Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B. 2007;111:10453-10460. (Pubitemid 47441849)
24. Marren K. Dimethyl sulfoxide: aneffective penetration enhancer for topical administration of NSAIDs. Phys Sportsmed. 2011; 39:75-82.
25. Galer BS. A comparative subjective assessment study of PENNSAID® and Voltaren Gel®, two topical formulations of diclofenac sodium. Pain Pract. 2011;11:252-260.
26. Bookman AA, Williams KS, Shainhouse JZ. Effect of atopical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171:333-338. (Pubitemid 39127985)
27. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety oftopical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo,DMSOvehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143:238-245.
28. Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv. 2005;2:489-505.
29. Jaksic I, Lukic M, Malenovic A, et al. Compounding of atopical drug with prospective natural surfactant-stabilized pharmaceutical bases: physiochemical and in vitro/in vivo characterization - a ketoprofen case study. Eur J Pharm Biopharm. January 2012;80(1):164-175.
30. Bachhav YG, Patravale VB. Formulation of meloxicam gel for topical application: in vitro and in vivo evaluation. Acta Pharm. 2010;60:153-163.
31. Pénzes T, Blazsó G, Aigner Z, Falkay G, Eros I. Topical absorption ofpiroxicam from organogels - in vitro and in vivo correlations. Int J Pharm. 2005;298:47-54. (Pubitemid 40834314)
32. Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy oftopical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sports Med. 2010;38:19-28.
33. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39:203-212.
34. Baer PA, Thomas LM, Shainhouse Z. Treatment ofosteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6:44-52.
35. Roth SH, Shainhouse JZ. Efficacy and safety af a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehiclecontrolled clinical trial. Arch Intern Med. 2004;164:2017-2023. (Pubitemid 39390559)
36. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of atopical diclofenac solution (Pennsaid®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31:2002-2012. (Pubitemid 39336727)